Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Solid Tumours Clinical Trial

Official title:

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Carboplatin on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00136578
• Other study ID #: KSP10014
• Status: Completed
• Phase: Phase 1
• First received: August 25, 2005
• Last updated: September 22, 2017
• Start date: October 20, 2004
• Est. completion date: October 25, 2006

Study information

• Verified date: September 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 25, 2006
• Est. primary completion date: October 25, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy.

• ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.

Exclusion criteria:

• Females who are pregnant or nursing.

• Pre-existing hemolytic anemia.

• Pre-existing peripheral neuropathy greater than or equal grade 2. Greater than or equal to 4 prior chemotherapy regimens including neoadjuvant/adjuvant chemotherapy, except breast cancer subjects who may have received more than 4 prior chemotherapy regimens.

• Absolute neutrophil count less than 1,500/mm3.

• Platelets less than 100,000/mm3.

• Hemoglobin less than 9 g/dL.

• Total bilirubin greater than1.5 mg/dL.

• AST/ALT greater than 2.5 X upper limit of normal.

• Creatinine clearance less than or equal to 50 mL/min (calculated by the Cockcroft Gault Formula).

• Known contra-indications to the use of carboplatin, cisplatin, or other platinum-containing compounds.

Related Conditions & MeSH terms

• Solid Tumours

Intervention

Drug:
• SB-715992
SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
• carboplatin
Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.

Locations

Country	Name	City	State
United Kingdom	GSK Investigational Site	Newcastle Upon Tyne	Northumberland
United States	GSK Investigational Site	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability endpoints will consist of the valuation of adverse events (AEs),vital signs and laboratory values. A dose regimen where = 1 of 6 (or =17%) subjects experience a dose-limiting toxicity.		Up to Day 154
Secondary	Antitumor activity will be assessed every 2 cycles and will be recorded as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).		Up to 140

External Links

•   Results for study KSP10014 can be found on the GSK Clinical Study Register.